Expanded Access of Sotorasib

Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients

NCT07143513 ·Status: COMPLETED

Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC

NCT06934590 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

NCT04603807 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

NCT04486833 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

NCT07083687 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

NCT06552234 ·Status: RECRUITING ·Phase: PHASE2

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

NCT06678555 ·Status: ACTIVE_NOT_RECRUITING

A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

NCT04395677 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC

NCT07294261 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

NCT02630186 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

NCT07230691 ·Status: RECRUITING

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

NCT06436144 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

NCT06564324 ·Status: RECRUITING ·Phase: PHASE3

ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

NCT00101920 ·Status: COMPLETED ·Phase: PHASE2

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

NCT05297890 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

NCT04304638 ·Status: UNKNOWN

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

NCT06706076 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation

NCT02883543 ·Status: UNKNOWN ·Phase: PHASE3

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

NCT06010329 ·Status: RECRUITING ·Phase: PHASE2

A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT05863325 ·Status: RECRUITING ·Phase: PHASE2

Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC

NCT06841874 ·Status: NO_LONGER_AVAILABLE

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

NCT02759835 ·Status: COMPLETED ·Phase: PHASE2

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT05168566 ·Status: RECRUITING ·Phase: PHASE2

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

NCT02927340 ·Status: UNKNOWN ·Phase: PHASE2

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

NCT01945021 ·Status: COMPLETED ·Phase: PHASE2